BEO Pharma Inc. dba BEO Pharmaceuticals
FDA inspection history in Brooksville, Florida, 2024 to 2025
- 1
- Warning letter
- 1
- Form 483
Every document, by year
- Warning letter
- Form 483
2024: one Form 483; 2025: one warning letter.
The story so far
Built from the dates and citations on the documents themselves.
- 2024–25One Form 483 and one warning letter, at Brooksville, Florida.
Cited most
Across all BEO Pharma Inc. dba BEO Pharmaceuticals observations on file
- 21 CFR 211.100(a)Written procedures; deviations1
- 21 CFR 211.160(b)General requirements1
- 21 CFR 211.165(a)Testing and release for distribution1
- 21 CFR 211.22(d)Responsibilities of quality control unit1
- 21 CFR 211.84(d)(1)Testing and approval or rejection of components, drug product containers, and closures1
The complete BEO Pharma Inc. dba BEO Pharmaceuticals file.
All 2 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.
The price of the documents, added to your cart together
Sites
Brooksville, Florida
One warning letter and one Form 483 · 2024 to 2025 · 5 observations
Latest: Warning letter, Apr 9, 2025 →
Documents
2 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2025-04-09 | Warning letter Warning letter | Brooksville, Florida | — | $99 |
| 2024-11-04 | 483 Form 483 | Brooksville, Florida | 5 | $99 |
Investigators on these documents
FEI number 3027036172 · most recent document Apr 9, 2025
About BEO Pharma Inc. dba BEO Pharmaceuticals
How many FDA Form 483s has BEO Pharma Inc. dba BEO Pharmaceuticals received?
FDA Intel has 1 Form 483 on file for BEO Pharma Inc. dba BEO Pharmaceuticals; the most recent is dated Nov 4, 2024.
When was BEO Pharma Inc. dba BEO Pharmaceuticals last inspected by FDA?
The most recent FDA inspection document on file for BEO Pharma Inc. dba BEO Pharmaceuticals is a Form 483 dated Nov 4, 2024, for the site in Brooksville, Florida.
What did FDA cite at BEO Pharma Inc. dba BEO Pharmaceuticals?
The regulations cited most in the observations on file for BEO Pharma Inc. dba BEO Pharmaceuticals are 21 CFR 211.100(a) (Written procedures; deviations), 1 time; 21 CFR 211.160(b) (General requirements), 1 time; 21 CFR 211.165(a) (Testing and release for distribution), 1 time.
Has BEO Pharma Inc. dba BEO Pharmaceuticals received an FDA warning letter?
Yes. FDA Intel has 1 FDA warning letter on file for BEO Pharma Inc. dba BEO Pharmaceuticals; the most recent is dated Apr 9, 2025.